Crohn’s Disease News and Research RSS Feed - Crohn’s Disease News and Research

TxCell announces launch of POSITIVE project to automate manufacturing process for Ovasave

TxCell SA, a biotech developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today the launch of, and funding awarded to, the POSITIVE project in collaboration with the Gene and Cell therapy Unit (UTCG) developing new antiviral cell-based immunotherapies and Biosafe, a Swiss private company, a developer of innovative solutions for cell processing. [More]
Tumor necrosis factor alpha antagonists not linked with increased risk of cancer

Tumor necrosis factor alpha antagonists not linked with increased risk of cancer

In a study that included more than 56,000 patients with inflammatory bowel disease, use of a popular class of medications known as tumor necrosis factor alpha antagonists was not associated with an increased risk of cancer over a median follow-up of 3.7 years, although an increased risk of malignancy in the long term, or with increasing number of doses, cannot be excluded, according to a study in the June 18 issue of JAMA. [More]
EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

EC approves Takeda's Entyvio for treatment of adults with ulcerative colitis, Crohn’s disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission has granted Marketing Authorisation for Entyvio (vedolizumab), a gut-selective humanized monoclonal antibody, and the first and only biologic therapy to be approved simultaneously for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNFα) antagonist. [More]

Gastroenterologists select efficacy over safety, tolerability when prescribing new drug for Crohn's disease

Decision Resources Group finds that, when asked to indicate the relative importance of product attributes when prescribing a new drug for Crohn's disease (CD), the highest percentages of surveyed gastroenterologists in the United States and Europe selected efficacy over safety and tolerability or delivery. [More]
FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). [More]
UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia (certolizumab pegol), the longest continuous trial of an anti-TNF therapy evaluating long-term safety in Crohn's disease. [More]
New study shows increase in certain macrophages may lead to therapeutic targets for Crohn's disease

New study shows increase in certain macrophages may lead to therapeutic targets for Crohn's disease

​For those coping with Crohn's disease, a new research report published in the Journal of Leukocyte Biology offers hope for the development of new and more effective drugs. In the report, scientists show for the first time, precisely what type of immune cells are involved in driving the inflammation process in the disease. [More]
Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Children newly diagnosed with Crohn's disease may benefit from biologic drugs

Children newly diagnosed with Crohn's disease may benefit from early treatment with the biologic drugs known as anti-TNF-α agents, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. [More]
Subset of TH17 cells linked to inflammation in Crohn’s disease patients, find TSRI scientists

Subset of TH17 cells linked to inflammation in Crohn’s disease patients, find TSRI scientists

Two-thirds to three-quarters of the estimated 700,000 Americans living with Crohn’s disease, an autoimmune condition that can disrupt the entire gastrointestinal tract, will require surgery at some point during their life. Patients and physicians often turn to this surgical intervention after a patient develops resistance to current treatments, such as steroids. [More]
TSRI scientists identify small subset of immune cells that play major role in development of Crohn's disease

TSRI scientists identify small subset of immune cells that play major role in development of Crohn's disease

Two-thirds to three-quarters of the estimated 700,000 Americans living with Crohn's disease, an autoimmune condition that can disrupt the entire gastrointestinal tract, will require surgery at some point during their life. [More]
AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

AGA guidelines recommend anti-TNF-α biologic agents to induce remission in Crohn's disease patients

The anti-TNF-α biologic agents, such as infliximab or adalimumab, are recommended to induce remission in patients with moderately severe Crohn's disease , according to a new guideline from the American Gastroenterological Association. Additionally, the guidelines recommend against using thiopurines or methotrexate alone to induce remission in these patients. The new guideline and accompanying technical review have been published in Gastroenterology, the official journal of the AGA Institute. [More]
FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. [More]
Keeping active reduces women’s Crohn’s risk

Keeping active reduces women’s Crohn’s risk

Regular exercise protects women against the development of Crohn’s disease, reveals research published in the BMJ. [More]
Specialized cells play major role in inflammation that underlies Crohn's disease in small intestine

Specialized cells play major role in inflammation that underlies Crohn's disease in small intestine

​Scientists have discovered that Crohn's disease, the inflammatory bowel disorder, can originate from specialised intestinal cell type called Paneth cells. As such, they propose that small intestinal Crohn's disease might be a specific disorder of this cell type, providing a possible new target for treatments. [More]
Abbvie, Galapagos Ink Up To $405M CF Collaboration

Abbvie, Galapagos Ink Up To $405M CF Collaboration

... [More]
Abbvie, Galapagos Ink Up To $405M CF Collaboration

Abbvie, Galapagos Ink Up To $405M CF Collaboration

... [More]
GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

... [More]

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

... [More]
RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

UCF College of Medicine professor Dr. Saleh Naser soon will participate in a clinical trial to test whether a new antibiotic therapy acquired by RedHill Biopharma can be used to treat Crohn's disease patients. [More]
Model including dozens of mutations helps clarify genetic factors involved in Crohn's disease

Model including dozens of mutations helps clarify genetic factors involved in Crohn's disease

​A statistical model accounting for dozens of different genes in combination-and the interactions between them-is an important step forward in understanding the genetic factors affecting the risk of Crohn's disease (CD), reports a study in Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America (CCFA). The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health. [More]